purposes of the working group are to discuss current knowledge related
to cost-effective analysis (CEA) in rare diseases, identify gaps in
this body of knowledge, and strategize next steps for incorporating CEA
into the evaluation of biobehavioral interventions. It is anticipated
that the working group will provide recommendations that will promote
the development of a research agenda that integrates this important
tool in the study of rare diseases.
Workgroup on integrating cost-effective analysis into clinical research